Skip to main content
. 2021 Apr;22(4):1217–1224. doi: 10.31557/APJCP.2021.22.4.1217

Figure 1.

Figure 1.

Survival Outcomes in the Combination Treatment and TACE Continuation Groups. (a), Time to extrahepatic spread; (b), Time to progression to advanced-stage disease; (c), Overall survival rate. CI, confidence interval; HR, hazard ratio; SOR, sorafenib; TACE, transarterial chemoembolization